# Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

> **NCT02824224** · PHASE4 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 42 (actual)

## Conditions studied

- Menorrhagia
- Metrorrhagia
- Medicated Intrauterine Devices

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Placebo (for Tamoxifen)

## Key facts

- **NCT ID:** NCT02824224
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-06
- **Primary completion:** 2018-01-08
- **Final completion:** 2018-01-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824224, "Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02824224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*